Emotional IntelligenceNCT06207266
Impact Emotional Intelligence Program on Opioid Relapse
A study testing emotion intelligence program in people with Emotional Intelligence and Opioid Use Disorder, run by Assiut University at 1 site in Egypt.
Trial summary
Addiction is the repeated and increased use of a substance, the deprivation of which gives rise to symptoms of distress and an irresistible urge to use the agent again and which leads also to physical and mental deterioration. Read more about this study
- Who is it for?
- Ages 18 to 60 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Emotional Intelligence, Opioid Use Disorder
- What is being tested?
- emotion intelligence program
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jan 2022to 1 Nov 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- in opioid groups: only opioid addiction
- in healthy groups: no history of psychiatric illness or substance use
Who cannot join
- have medical conditions
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Prospective Study of the Impact of an Emotional Intelligence Program on Opioid Relapse and Its Determinants
Addiction is the repeated and increased use of a substance, the deprivation of which gives rise to symptoms of distress and an irresistible urge to use the agent again and which leads also to physical and mental deterioration. The concept of emotional intelligent (EI) "the ability to perceive accurately, appraise and express emotion; the ability to access and generate feelings when they facilitate thought; the ability to understand emotion and emotional knowledge; and the ability to regulate emotions to promote emotional and intellectual growth". Most drug addicts possess hidden defects in their social skills, and do not have good relations with their peers.
Read the detailed description
Addiction is the repeated and increased use of a substance, the deprivation of which gives rise to symptoms of distress and an irresistible urge to use the agent again and which leads also to physical and mental deterioration. Continued opioid misuse can result in syndromes of abuse and dependence and cause disturbances in mood, behavior, and cognition that can mimic other psychiatric disorders. Opioid addiction affects the young and the old, the wealthy and the poor, and the professional and the unemployed.
The concept of emotional intelligent (EI) "the ability to perceive accurately, appraise and express emotion; the ability to access and generate feelings when they facilitate thought; the ability to understand emotion and emotional knowledge; and the ability to regulate emotions to promote emotional and intellectual growth", the ability to manage and regulate emotions in an effective manner and ability to be sufficiently optimistic, positive and self- motivated in order to set and achieve goals.
Most drug addicts possess hidden defects in their social skills, and do not have good relations with their peers. The other possible causes of orienting toward drugs are defects in problem solving, stress-management, and prevention from dangerous and impulsive behaviors.
- Conditions
- Emotional Intelligence, Opioid Use Disorder
- Being tested
- emotion intelligence program
- Medical subject headings
- Opioid-Related Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
emotion intelligence programBehavioural
The programme was established using research that described emotional intelligence components and their applicability to patients suffering from substance abuse. it considers as awareness program.
| Study group | Role | What they receive |
|---|---|---|
| Participants with opioid use disorder group with emotion intelligence program (n=20) | Experimental | Participants with opioid use disorder group who had emotion intelligence program to increase aware about definition, component, how to deal with EI to reduce relapse rate. Receives: Behavioral: emotion intelligence program |
| Participants with opioid use disorder group without intelligence program (n=20). | No intervention | Participants with opioid use disorder group who had traditional medical treatment only |
| A healthy group (n=20) served as a control group. | No intervention | A healthy group who did not have history of psychiatric illness or substance use. |
What is being measured
The primary outcome is the main question the study is designed to answer.
measure level of emotion intelligence in opioid addiction
Measure the level of emotional intelligence. The scale consists of sixty objects classified into six distinct domains. A four-point Likert scale is employed, which spans from 1 (indicating never) to 4 (indicating always). The percentages represent the scores; emotional intelligence ranges (from 0-100%), and higher scores mean a high level of emotional intelligence.
Measured: through study completion, an average of 1 year
develop an EI programme to prevent relapses in addiction.
An emotional intelligence (EI) program was developed and implemented for patients in the hospital. Emotion intelligence scale was measured at baseline prior to starting the EI program. The EI program was then administered to patients during their hospital stay. Emotion intelligence scale assessments were conducted at discharge from the hospital and again 3 months after discharge. Regarding EI program sessions took place in the recreation hall, where material such as videos and booklets containing content on emotional intelligence skills was presented.
Measured: through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jan 2024
- Study start1 Jan 2022
- Primary completion1 Nov 2022
- Study completion1 Nov 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Emotional IntelligenceStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants with opioid use disorder were divided into two groups: group with emotion intelligence program (n=20) and group without intelligence program (n=20). A healthy group (n=20) served as a control group.
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Gellan Karamalllah Ramadan Ahmed, Assiut University
- Investigators
- gellan Karamallah R Ahmed, Study director, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06207266
- Sponsor's protocol ID
- EMOTION INTELLIGENCE
- Status last verified
- Jan 2024
- First submitted
- 17 Dec 2023
- Last updated
- 17 Jan 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Jan 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Study of the Impact of an Emotional Intelligence Program on Opioid Relapse and Its Determinants
- ClinicalTrials.gov ID
- NCT06207266
- Acronym / sponsor ID
- EMOTION INTELLIGENCE
- Conditions
- Emotional Intelligence, Opioid Use Disorder
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Jan 2022 (actual)
- Primary completion
- 1 Nov 2022 (actual)
- Study completion
- 1 Nov 2023 (actual)
- First posted
- 16 Jan 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Addiction is the repeated and increased use of a substance, the deprivation of which gives rise to symptoms of distress and an irresistible urge to use the agent again and which leads also to physical and mental deterioration. The concept of emotional intelligent (EI) "the ability to perceive accurately, appraise and express emotion; the ability to access and generate feelings when they facilitate thought; the ability to understand emotion and emotional knowledge; and the ability to regulate emotions to promote emotional and intellectual growth". Most drug addicts possess hidden defects in their social skills, and do not have good relations with their peers.
Detailed description
Addiction is the repeated and increased use of a substance, the deprivation of which gives rise to symptoms of distress and an irresistible urge to use the agent again and which leads also to physical and mental deterioration. Continued opioid misuse can result in syndromes of abuse and dependence and cause disturbances in mood, behavior, and cognition that can mimic other psychiatric disorders. Opioid addiction affects the young and the old, the wealthy and the poor, and the professional and the unemployed.
The concept of emotional intelligent (EI) "the ability to perceive accurately, appraise and express emotion; the ability to access and generate feelings when they facilitate thought; the ability to understand emotion and emotional knowledge; and the ability to regulate emotions to promote emotional and intellectual growth", the ability to manage and regulate emotions in an effective manner and ability to be sufficiently optimistic, positive and self- motivated in order to set and achieve goals.
Most drug addicts possess hidden defects in their social skills, and do not have good relations with their peers. The other possible causes of orienting toward drugs are defects in problem solving, stress-management, and prevention from dangerous and impulsive behaviors.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 3
- Model description
- Participants with opioid use disorder were divided into two groups: group with emotion intelligence program (n=20) and group without intelligence program (n=20). A healthy group (n=20) served as a control group.
| Arm | Type | Receives |
|---|---|---|
| Participants with opioid use disorder group with emotion intelligence program (n=20) | Experimental | Behavioral: emotion intelligence programParticipants with opioid use disorder group who had emotion intelligence program to increase aware about definition, component, how to deal with EI to reduce relapse rate. |
| Participants with opioid use disorder group without intelligence program (n=20). | No intervention | –Participants with opioid use disorder group who had traditional medical treatment only |
| A healthy group (n=20) served as a control group. | No intervention | –A healthy group who did not have history of psychiatric illness or substance use. |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- in opioid groups: only opioid addiction
- in healthy groups: no history of psychiatric illness or substance use
Key exclusion criteria (1 listed)
- have medical conditions
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| emotion intelligence programThe programme was established using research that described emotional intelligence components and their applicability to patients suffering from substance abuse. it considers as awareness program. | Behavioural | Participants with opioid use disorder group with emotion intelligence program (n=20) |
Primary outcome
measure level of emotion intelligence in opioid addiction
Time frame: through study completion, an average of 1 year
Measure the level of emotional intelligence. The scale consists of sixty objects classified into six distinct domains. A four-point Likert scale is employed, which spans from 1 (indicating never) to 4 (indicating always). The percentages represent the scores; emotional intelligence ranges (from 0-100%), and higher scores mean a high level of emotional intelligence.
develop an EI programme to prevent relapses in addiction.
Time frame: through study completion, an average of 1 year
An emotional intelligence (EI) program was developed and implemented for patients in the hospital. Emotion intelligence scale was measured at baseline prior to starting the EI program. The EI program was then administered to patients during their hospital stay. Emotion intelligence scale assessments were conducted at discharge from the hospital and again 3 months after discharge. Regarding EI program sessions took place in the recreation hall, where material such as videos and booklets containing content on emotional intelligence skills was presented.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jan 2024.
Related trials for Emotional Intelligence
Not yet recruiting
AI-Supported CBT-Based Psychoeducation for Caregivers of Individuals With Schizophrenia
Schizophrenia Caregiver, Caregiver Burden
Enrolling by invitationObservational study
NeuroFinance Human Stress Trial During Financial and Informational Volatility
Psychological Stress, Anxiety
Not yet recruiting
Effect of AI-Assisted Expressive Writing on Anxiety, Emotional Distress, and Quality of Life Among Patients Receiving Chemotherapy
Cancer, Chemotherapy
Active, not recruiting
Psychosocial Correlates of Trait Emotional Intelligence and Psychosomatic Symptoms Among Adolescents Exposed to Bullying and the Effects of Mindfulness-Based Stress Reduction.
Childhood Trauma, Stress
Active, not recruiting
AI-Assisted Mindfulness Intervention in Emotional Distress
Subclinical Depression, Subclinical Anxious Adults
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
gellan Karamallah R Ahmed study director
Assiut University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing emotion intelligence program in people with Emotional Intelligence and Opioid Use Disorder, run by Assiut University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
measure level of emotion intelligence in opioid addiction (time frame: through study completion, an average of 1 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jan 2024.